Last reviewed · How we verify
NCT03935295
Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis
Phase 4 trial testing AbobotulinumtoxinA in Adolescent Idiopathic Scoliosis in 90 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Johns Hopkins University |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 3 September 2020 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- AbobotulinumtoxinA — full drug profile →
- Placebos — full drug profile →
- Custom Thoracolumbosacral Orthosis
Conditions studied
- Adolescent Idiopathic Scoliosis — all drugs for Adolescent Idiopathic Scoliosis →
Sponsor
Johns Hopkins University
Who can join
Adults 10 to 16, any sex, with Adolescent Idiopathic Scoliosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the combined effect of botulinum toxin A (administered as Dysport® (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two thirds of patients will be treated with Dysport® and bracing, while the remaining patients will be treated with placebo and bracing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03935295
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AbobotulinumtoxinA
Trials testing the same drug.
- NCT05466539 — Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A · Phase 4 · completed
- NCT05089357 — Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin · completed
- NCT04886167 — Dysport Dose-Ranging Treatment of Platysmal Bands · Phase 1, PHASE2 · unknown
- NCT03960957 — Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines · Phase 3 · completed
- NCT04470401 — The Treatment of Shoulder Pain in Hemiplegic Spastic Patients With Botulinum Toxin A · Phase 4 · completed
Other recruiting trials for Adolescent Idiopathic Scoliosis
Currently open trials in the same condition.
- NCT07249515 — Scapula and Upper Extremity Performance in Scoliosis · recruiting
- NCT07430098 — Feedback-Based Balance Training for Adolescents With Idiopathic Scoliosis · NA · active not recruiting
- NCT06680297 — Preoperative Carbohydrate Drink in Adolescent Idiopathic Scoliosis Surgery: the Impact on Safety and Enhanced Recovery · NA · recruiting
- NCT06279468 — Clinical Effectiveness of Intervertebral Disc Release in Treating Lenke 5 Adolescent Idiopathic Scoliosis · NA · recruiting
- NCT06416579 — Comparison of the Efficiency of Schroth Method and Virtual Reality Exercises in Individuals With AIS · NA · recruiting
Other Johns Hopkins University trials
Trials by the same sponsor.
- NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
- NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
- NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
- NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
- NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03935295 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03935295.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing